Thursday, May 26, 2016

BRIEF-AstraZeneca receives complete response letter from U.S. FDA for sodium zirconium cyclosilicate

* Astrazeneca receives complete response letter from us fda

for sodium zirconium cyclosilicate (zs-9) for oral suspension

for treatment of hyperkalaemia

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)